Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer
Status:
Recruiting
Trial end date:
2024-12-30
Target enrollment:
Participant gender:
Summary
The purpose of this clinical study is to confirm the utility of chemosensitivity (ChemoID)
tumor testing on cancer stem cells as a predictor of clinical response in recurrent platinum
resistant epithelial ovarian cancer (EOC), fallopian tube, or primary peritoneal cancer.
Population studied will be female participants experiencing a recurrent platinum-resistant
ovarian cancer (no mucinous, low grade serous, or pure sarcoma types), with ≤ 5 prior
treatments, and a performance status 0-1.